Some patients who experience drug-induced liver injury (DILI) develop a persistent cholestatic pattern that does not fully resolve after withdrawal of the offending agent. This chronic cholestatic presentation requires a specific treatment approach.
This protocol targets patients with chronic cholestasis following DILI — where cholestatic dysfunction persists beyond the acute drug-induced liver injury event. Addressing this ongoing presentation is key to limiting further hepatic damage.
The management of chronic cholestasis in this setting centres on a bile acid agent — ursodeoxycholic acid (UDCA) forms the basis of the approach. The complete protocol specifies the full regimen structure, dosing parameters, and monitoring guidance beyond what is outlined here.
DOI: 10.1016/j.jhep.2019.02.014
Chronic cholestasis following DILI is often treated with ursodeoxycholic acid (UDCA).
View source ↗